Evolution Bioscience | Kala Pharmaceuticals

';

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

Recent Comments

Recent Posts

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution? August 13, 2018
Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015 July 13, 2018

Unknown Feed

Search

Tag Cloud

Agricultural Technology AstraZeneca Bayer Bio-Rad Biopharma Bioproduction Biotech bluebird bio Boehringer Ingelheim Cancer Immunotherapy Celgene Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Evolution Global Press Releases Evolution Infographics GE Healthcare Genentech Gene Therapy Genomics & Proteomics GSK Illumina Informatics & Analytics Johnson & Johnson Juno Therapeutics KITE Pharma Life Sciences Lonza Medical Devices Merck Mergers Partnerships & Acquisitions Metagenomics MilliporeSigma Next Generation Sequencing Novartis Pfizer Regenerative Medicine Roche Sanofi Sartorius Stedim Sigma-Aldrich The Future of BioManufacturing Thermo Fisher Scientific

Text

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In in lorem sit amet ligula feugiat vulputate vel vitae quam. Cras posuere imperdiet lorem, in aliquam urn

CategoriesTitle

Evolution Infographics
News & Analysis

ArchivesTitle

Cat tabs

: First
: Second
: Third

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015

Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

+44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search

Home
Clients & Core Services
News & Analysis
- The Future of BioManufacturing
IPO Tracker

Kala Pharmaceuticals

Evolution Infographics

2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Bearish Q3

2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Bearish Q3

More

Share

Search

THE FUTURE OF BIOMANUFACTURING

Browse By Category

Agricultural Technology Bioinformatics Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Line Engineering Cell Therapy Chemicals CRO/CMO Diagnostics Downstream Processing Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Modular Factories Molecular Pathology Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

Browse By Company

ACD Bio AstraZeneca Bayer Bio-Rad bluebird bio Boehringer Ingelheim Celgene Evolution Global Press Releases GE Healthcare Genentech GSK Illumina Johnson & Johnson Juno Therapeutics KITE Pharma Lonza Merck MilliporeSigma Novartis Pfizer Roche Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific

RECENT POSTS

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015

Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results

DATA VISUALISATIONS

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015

Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

About Us

Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

Get In Touch

+44 141 248 2026

info@evolution-bio.com

Recent Posts

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015

Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015

Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

BROWSE NEWS BY INDUSTRY

Agricultural Technology Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

BROWSE NEWS BY COMPANY

Bayer Bio-Rad bluebird bio Celgene Evolution Global Press Releases Genentech GSK Illumina Juno Therapeutics KITE Pharma Lonza Merck MilliporeSigma Novartis Pfizer Roche Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific

2016 © Evolution Bioscience / Darwin Hutton Partners

Search for: